Mesoblast International Sàrl
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
4
Ending by 2030
Jan 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 27, 2026The maintenance fee for Cell Culture Method for Mesenchymal Stem Cells (US 11,685,899) comes due Dec 27, 2026. Unpaid by Jun 28, 2027, it lapses early.
- 1 fee due Feb 1, 2027The maintenance fee for Method for Treating Heart Failure (US 11,712,452) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
- 1 fee due Mar 3, 2027The maintenance fee for Improved Stem Cell Composition (US 10,400,218) comes due Mar 3, 2027. Unpaid by Sep 3, 2027, it lapses early.
- 2 fees due Apr 24 to 29, 2027 · next Apr 24
- 1 fee due Aug 4, 2027The maintenance fee for Enhanced MSC Preparation (US 10,550,369) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
- 2 fees due Oct 12 to 21, 2027 · next Oct 12
Recent changes
- 1 term has ended since Aug 22, 2026
- Sep 15 US 11,389,484 Mesenchymal Stem Cells and Uses Therefor · term ended
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,486,695 | Mesenchymal Stem Cells Expressing TNF-alpha Receptors In force · High confidence | In force | High confidence | |
| US 11,821,004 | Mesenchymal Stem Cells Expressing TNF-alpha Receptors In force · High confidence | In force | High confidence | |
| US 7,696,309 | Protease Resistant Mutants of Stromal Cell Derived FACTOR-1 in the Repair of Tissue Damage In force · High confidence | In force | High confidence | |
| US 7,999,067 | Protease Resistant Mutants of Stromal Cell Derived FACTOR-1 in the Repair of Tissue Damage In force · High confidence | In force | High confidence | |
| US 10,456,451 | Protease-Resistant Mutants of Stromal Cell Derived FACTOR-1 in the Repair of Tissue Damage In force · High confidence | In force | High confidence | |
| US 9,828,586 | Enhanced MSC Preparations In force · Medium confidence | In force | Medium confidence | |
| US 9,963,678 | Enhanced MSC Preparations In force · Low confidence | In force | Low confidence | |
| US 11,708,560 | Enhanced MSC Preparations In force · Low confidence | In force | Low confidence | |
| US 12,410,405 | Enhanced MSC Preparations In force · High confidence | In force | High confidence | |
| US 9,308,277 | Protease-Resistant Mutants of Stromal Cell Derived FACTOR-1 in the Repair of Tissue Damage In force · High confidence | In force | High confidence |
Also on record, not counted in the 28: 3 lapsed for an unpaid fee · 54 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
16 pending · 19 abandoned · 3 no status recorded